BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oi N, Suzuki M, Terauchi T, Tokunaga M, Nakatani Y, Yamamoto N, Fukumura T, Zhang M, Suhara T, Higuchi M. Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor. J Med Chem 2013;56:6371-85. [DOI: 10.1021/jm400772t] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Bai P, Liu Y, Xu Y, Striar R, Yuan G, Afshar S, Langan AG, Rattray AK, Wang C. Synthesis and characterization of a new Positron emission tomography probe for orexin 2 receptors neuroimaging. Bioorg Chem 2022;123:105779. [PMID: 35397430 DOI: 10.1016/j.bioorg.2022.105779] [Reference Citation Analysis]
2 Watanabe H, Fukui K, Shimizu Y, Idoko Y, Nakamoto Y, Togashi K, Saji H, Ono M. Synthesis and biological evaluation of F-18 labeled tetrahydroisoquinoline derivatives targeting orexin 1 receptor. Bioorganic & Medicinal Chemistry Letters 2019;29:1620-3. [DOI: 10.1016/j.bmcl.2019.04.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
3 Boss C, Roch C. Recent trends in orexin research—2010 to 2015. Bioorganic & Medicinal Chemistry Letters 2015;25:2875-87. [DOI: 10.1016/j.bmcl.2015.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 6.7] [Reference Citation Analysis]
4 Obokata N, Seki C, Hirata T, Maeda J, Ishii H, Nagai Y, Matsumura T, Takakuwa M, Fukuda H, Minamimoto T, Kawamura K, Zhang MR, Nakajima T, Saijo T, Higuchi M. Synthesis and preclinical evaluation of [11C]MTP38 as a novel PET ligand for phosphodiesterase 7 in the brain. Eur J Nucl Med Mol Imaging 2021;48:3101-12. [PMID: 33674894 DOI: 10.1007/s00259-021-05269-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Boss C. Orexin receptor antagonists--a patent review (2010 to August 2014). Expert Opin Ther Pat 2014;24:1367-81. [PMID: 25407283 DOI: 10.1517/13543776.2014.978859] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
6 Koga K, Maeda J, Tokunaga M, Hanyu M, Kawamura K, Ohmichi M, Nakamura T, Nagai Y, Seki C, Kimura Y, Minamimoto T, Zhang MR, Fukumura T, Suhara T, Higuchi M. Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H3 receptors. EJNMMI Res 2016;6:11. [PMID: 26860293 DOI: 10.1186/s13550-016-0170-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
7 Watanabe H, Idoko Y, Iikuni S, Ide T, Shimizu Y, Nakamoto Y, Ono M. Synthesis and biological evaluation of novel 18F-labeled phenylbenzofuran-2-carboxamide derivative for detection of orexin 1 receptor in the brain. Bioorg Med Chem Lett 2021;43:128098. [PMID: 33984472 DOI: 10.1016/j.bmcl.2021.128098] [Reference Citation Analysis]
8 Lu S, Siméon FG, Telu S, Cai L, Pike VW. The chemistry of labeling heterocycles with carbon-11 or fluorine-18 for biomedical imaging. Elsevier; 2020. pp. 241-384. [DOI: 10.1016/bs.aihch.2019.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
9 Watanabe H, Matsushita N, Shimizu Y, Iikuni S, Nakamoto Y, Togashi K, Ono M. Synthesis and characterization of a novel 18F-labeled 2,5-diarylnicotinamide derivative targeting orexin 2 receptor. Medchemcomm 2019;10:2126-30. [PMID: 32904113 DOI: 10.1039/c9md00397e] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Mann A, Han H, Eyal S. Imaging transporters: Transforming diagnostic and therapeutic development. Clin Pharmacol Ther 2016;100:479-88. [PMID: 27327047 DOI: 10.1002/cpt.416] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
11 Zhou YP, Makaravage KJ, Brugarolas P. Radiolabeling with [11C]HCN for Positron emission tomography. Nucl Med Biol 2021;102-103:56-86. [PMID: 34624831 DOI: 10.1016/j.nucmedbio.2021.09.002] [Reference Citation Analysis]
12 Oi N, Tokunaga M, Suzuki M, Nagai Y, Nakatani Y, Yamamoto N, Maeda J, Minamimoto T, Zhang M, Suhara T, Higuchi M. Development of Novel PET Probes for Central 2-Amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic Acid Receptors. J Med Chem 2015;58:8444-62. [DOI: 10.1021/acs.jmedchem.5b00712] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
13 Taddei C, Gee AD. Recent progress in [11 C]carbon dioxide ([11 C]CO2 ) and [11 C]carbon monoxide ([11 C]CO) chemistry. J Labelled Comp Radiopharm 2018;61:237-51. [PMID: 29274276 DOI: 10.1002/jlcr.3596] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 8.8] [Reference Citation Analysis]
14 Thompson S, Kealey S, Sephton SM, Aigbirhio FI. Radiochemistry with Carbon‐11. In: Scott P, Kilbourn M, editors. Handbook of Radiopharmaceuticals. Wiley; 2020. pp. 143-249. [DOI: 10.1002/9781119500575.ch7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Gao M, Wang M, Zheng Q. Synthesis of [11C]MK-1064 as a new PET radioligand for imaging of orexin-2 receptor. Bioorganic & Medicinal Chemistry Letters 2016;26:3694-9. [DOI: 10.1016/j.bmcl.2016.05.083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
16 Yuan S, Yu B, Liu H. New drug approvals for 2019: Synthesis and clinical applications. European Journal of Medicinal Chemistry 2020;205:112667. [DOI: 10.1016/j.ejmech.2020.112667] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]